Harrison AI: Company, Products and 2026 Overview

Harrison AI, usually written as Harrison.ai, is an Australian artificial intelligence company focused on medical imaging and radiology software. The company develops tools for areas such as chest X-ray and CT imaging, while also building radiology-focused foundation models for research.

In 2026, Harrison.ai has continued expanding internationally, releasing Harrison.Rad 1.5, adding partners to its Open Platform, and announcing additional product clearances and hospital deployments.

What is Harrison AI?

Harrison.ai was founded in Australia and builds artificial intelligence products for radiology workflows. Its technology is designed to help radiologists review imaging more efficiently by highlighting findings, prioritising cases, and supporting reporting workflows depending on the specific product.

The company operates across several markets and has announced partnerships and deployments in Australia, the United Kingdom, the United States, India, Indonesia, and other regions.

What products does Harrison.ai offer?

Harrison.ai’s commercial radiology portfolio includes tools for imaging categories such as chest X-ray, CT brain, and CT chest. The company also operates the Harrison Open Platform, which is intended to let healthcare organisations access multiple AI products through one platform.

Exact features, regulatory status, and availability differ by product and country. Readers should check the official product page for the market they are in rather than assuming every feature is available everywhere.

What is Harrison.Rad 1.5?

Harrison.Rad 1.5 is a radiology-specific multimodal foundation model released in June 2026. Harrison.ai says it can work with images and text, including prior studies and clinical context, to produce draft radiology reports for research use.

The company states that the model was trained on approximately 6 million medical imaging studies and 18 million clinically crafted instruction pairs.

Harrison.ai also clearly states that Harrison.Rad 1.5 has not been cleared for clinical use and is intended for research. That distinction is important when comparing it with Harrison.ai’s regulated commercial products.

How is Harrison.ai different from general-purpose AI tools?

General-purpose models are built to handle many kinds of tasks. Harrison.ai’s models and products are designed around radiology and medical imaging.

Area	Harrison.ai	General-purpose AI
Main focus	Radiology and medical imaging	Broad text, image, coding and reasoning tasks
Training emphasis	Domain-specific medical imaging data and workflows	General multimodal or language data
Regulated products	Some commercial products have market-specific clearances	Usually not designed as regulated radiology devices
Research models	Harrison.Rad family	General frontier models

What is the Harrison Open Platform?

The Harrison Open Platform is designed to give organisations access to Harrison.ai products alongside selected third-party AI tools. In March 2026, Harrison.ai announced four additional AI partners joining the platform.

The platform approach reflects a practical issue in radiology: one hospital may need different tools for X-ray, CT, MRI, mammography, and ultrasound workflows.

Where is Harrison.ai being used?

Harrison.ai has announced deployments and partnerships across multiple countries. In April 2026, the company announced rollout of chest X-ray and CT brain support solutions across the Kasih Ibu Hospital Group in Bali, Indonesia.

Its public materials also describe adoption across health systems in several other regions. Deployment does not automatically mean every product is identical in each market, because local regulation and workflow requirements differ.

What are the main Harrison.ai developments in 2026?

• Launch of Harrison.Rad 1.5 for research.
• Continued expansion of the Harrison Open Platform.
• Additional international deployments and partnerships.
• New regulatory milestones for specific commercial products.
• More published technical and evidence material around radiology AI.

Our separate AI news coverage tracks related developments across the wider artificial intelligence industry.

How should readers evaluate Harrison.ai claims?

Company announcements are useful primary sources for product launches and partnerships, but performance claims should be read in context. A benchmark result, regulatory clearance, and real-world deployment each answer a different question.

1. Check whether the claim comes from the company, an independent study, or a regulator.
2. Confirm which product the claim applies to.
3. Check whether the product is for research or clinical use.
4. Look for independent evidence when evaluating performance.
5. Verify regional availability before assuming a feature is offered locally.

For broader AI evaluation principles, see our best AI tools in 2026 guide.

Frequently Asked Questions

Is Harrison AI the same as Harrison.ai?

Yes. People often search for “Harrison AI,” while the company brands itself as Harrison.ai.

Is Harrison.ai only a research company?

No. It develops commercial radiology products as well as research-focused foundation models.

Is Harrison.Rad 1.5 a clinical product?

No. Harrison.ai says Harrison.Rad 1.5 is a research model and has not been cleared for clinical use.

Bottom line

Harrison AI is a specialised AI company focused on radiology rather than a general consumer chatbot company. Its 2026 strategy combines regulated imaging products, research foundation models, international deployment, and an open platform that can include third-party tools.

The most useful way to understand Harrison.ai is to separate its research models from its commercial products and to check the evidence and regulatory status attached to each one.

Readers looking for a dated update can continue with our latest Harrison AI news summary.

Sources consulted

• Harrison.ai official website, Newsroom, and Resources pages.
• Harrison.Rad 1.5 launch announcement, June 9, 2026.
• Harrison.ai Open Platform announcement, March 4, 2026.
• Harrison.ai Kasih Ibu Hospitals deployment announcement, April 23, 2026.

Editorial transparency: This article uses public company information and distinguishes research models from regulated commercial products. Product availability and regulatory status can change by market. This is general information, not medical advice.